spacer
home > pmps > summer 2008 > recasting legislation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Recasting Legislation

When the European Commission published its public consultation document concerning the recast of the current EU provisions governing medical devices on 7th May 2008, this did not come as a great surprise to the informed public. In its ‘Communication to the European Parliament and the Council’ in 2005 on Implementing the Community Lisbon programme the Commission had already indicated its intention to recast two of the three basic EU Directives governing medical devices into a simplified regulation.

While the subsequent proposal may have been “much awaited” (as the Commission’s own press release claimed) it was not in the form of a regulation. Moreover, there was a certain level of disappointment that the proposal, as finally submitted, did not constitute the overhaul of the existing medical device legislation that was hoped for in at least some corners.

No explanation as to the change of legislative approach was provided in either the impact assessment report for the Commission’s proposal or in the explanatory memorandum that accompanied the proposal. Moreover, even before the resultant modifications to Directive 90/385/EEC (1) and Directive 93/42/EEC (2) had been adopted, there were already rumblings that it was time for a complete revision of EU medical device law. While the EU member states are still implementing the last set of amendments to the medical devices directives, and manufacturers continue to determine the likely impact of these for their products, the Commission is proposing a revision of this existing framework in order “to improve and strengthen the legal framework for the regulation of medical devices in Europe”.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Elisabethann Wright has been practicing European law for more than 20 years. Her practice focuses largely on EU regulation of medical devices and pharmaceutical products. She has extensive experience in litigation before the European Court. Having successfully challenged decisions of the EU institutions before the European Courts, she also advises on EU law relating to government contracts.

Fabien Roy, a Legal Assistant in the Hogan & Hartson Brussels office, researches and assists in drafting legal opinions in the field of pharmaceutical law, and communicates regularly with the relevant authorities. He drafts reports on fields including: paediatrics, biosimilars, authorisation and control of pharmaceuticals, regulatory initiatives, oncology and diabetes. Fabien holds a degree of Public Law from the University of Silesia, and a Master’s Degree from the University of Rennes. Email: ewright@hhlaw.com

spacer
Fabien Roy
spacer
spacer
spacer
Elisabethann Wright
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Launches ADC ExpressTM Services to Accelerate Pre-clinical Conjugation Candidate Selection

• Provides rapid production of antibody drug conjugates (ADCs) for best candidate selection • Established platform technology to reliably scale target molecules • Reduces time to clinic through comprehensive ADC services from pre-clinical to commercial from a single source
More info >>

White Papers

Conveying Medical Guidance in Clinical Trials – A Survey

Europital Medical Consultancy

With the incremental demand for proactive safety surveillance throughout the conduct of clinical trials, the role of Medical Management is at the fore in ensuring the safety and wellbeing of the participants. The complex responsibilities of a Medical Monitor (MM) starts from the design and development phase, through to study close out. Understanding the principle behind the protocol and the prospective medical solution the study would deliver forms the bloodline for the MM role. Often, the MM is the face of contact for both the site personnel and the study team members with regard to medical, safety and scientific issues within the project. When it comes to medical guidance, the communication channel used to deliver solutions contributes to a large extent in effectively managing decisive situations. Our previous study on acquiring medical guidance from an operations team perspective revealed that e-mails were the most used communication method (see the article, 'Talking Points', in ICT November 2014). In our efforts to further strengthen the mode of medical guidance delivery, we designed a survey to study the existing trend and constraints in this communication chain management, as outlined here.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement